Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
METR-NK cells
- Development stage
- Phase 2
- Lead developer
- Anhui Kecheng Intelligent Health Technology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
METR-NK cells (metabolic remodeling natural killer cells) are an investigational adoptive cell therapy consisting of natural killer (NK) cells that have been metabolically reprogrammed to enhance their survival, persistence, and functional activity. Developed by Anhui Provincial Cancer Hospital, this therapy is being evaluated in Phase 1/2 clinical trials for the prevention of chemotherapy-induced myelosuppression (bone marrow suppression) in patients with ovarian cancer. The treatment involves the intravenous infusion of at least 2×10^7 cells/kg, typically administered approximately 10 days prior to chemotherapy. By optimizing the metabolic pathways of the NK cells, the treatment aims to provide hematopoietic support and potentially enhance anti-tumor immunity when used as an adjuvant to standard chemotherapy regimens.
- Other names
- metabolic remodeling nature killer cellsMETR-NK cell
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on METR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on METR-NK cells.